Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex
© Long et al.; licensee BioMed Central Ltd. 2012
Received: 4 February 2012
Accepted: 28 June 2012
Published: 24 July 2012
Endocannabinoids provide control over cortical neurotransmission. We investigated the developmental expression of key genes in the endocannabinoid system across human postnatal life and determined whether they correspond to the development of markers for inhibitory interneurons, which shape cortical development. We used microarray with qPCR validation and in situ hybridisation to quantify mRNA for the central endocannabinoid receptor CB1R, endocannabinoid synthetic enzymes (DAGLα for 2-arachidonylglycerol [2-AG] and NAPE-PLD for anandamide), and inactivating enzymes (MGL and ABHD6 for 2-AG and FAAH for anandamide) in human dorsolateral prefrontal cortex (39 days - 49 years).
CB1R mRNA decreases until adulthood, particularly in layer II, after peaking between neonates and toddlers. DAGLα mRNA expression is lowest in early life and adulthood, peaking between school age and young adulthood. MGL expression declines after peaking in infancy, while ABHD6 increases from neonatal age. NAPE-PLD and FAAH expression increase steadily after infancy, peaking in adulthood.
Stronger endocannabinoid regulation of presynaptic neurotransmission in both supragranular and infragranular cortical layers as indexed through higher CB1R mRNA may occur within the first few years of human life. After adolescence, higher mRNA levels of the anandamide synthetic and inactivating enzymes NAPE-PLD and FAAH suggest that a late developmental switch may occur where anandamide is more strongly regulated after adolescence than earlier in life. Thus, expression of key genes in the endocannabinoid system changes with maturation of cortical function.
The output of principal cortical neurons is regulated by a network of inhibitory interneurons [1, 2]. Coordinated development of these neurons underlies the acquisition and adaptation of visual, motor and cognitive function throughout postnatal life. Cognitive development during critical periods such as toddlerhood and adolescence is characterised by rapid acquisition of executive functions such as language, goal-directed behaviour and working memory [3–5]. This development is subserved by processes that facilitate a balance between excitatory and inhibitory transmission such as synaptogenesis [6–8], maturation of inhibitory interneurons , development of GABA receptors [10–12] and an early-life switch from excitatory to inhibitory actions of GABA [13–15].
The endogenous cannabinoid (endocannabinoid) system modulates excitatory-inhibitory balance by mediating short- and long-term synaptic plasticity. Cannabinoid CB1 receptors (CB1R) are thought to be primarily localised to presynaptic terminals of inhibitory GABAergic interneurons that express the neuropeptide cholecystokinin (CCK) and target the soma or proximal dendrite of pyramidal neurons in the primate dorsolateral prefrontal cortex (DLPFC) and primate and rodent hippocampus [16–18]. In addition, CB1Rs have been shown to co-localise with the calcium-binding proteins calbindin and calretinin in distinct subsets of cortical inhibitory interneurons [16, 18–20]. CB1Rs are also localised to some principal neurons in the hippocampus and the cerebellar cortex [21–23], although the current consensus is that they are expressed at much lower levels on these cells than in inhibitory interneurons . While endocannabinoids signal via a number of other receptors in addition to CB1, the major mode by which they interact with CB1Rs is via retrograde signalling. Following membrane depolarisation, increased Ca2+ concentration or metabotropic glutamate receptor activation, endocannabinoid ligands are synthesised in the postsynaptic terminal. Postsynaptic release and retrograde diffusion of endocannabinoids results in presynaptic CB1R activation and suppression of neurotransmitter release from presynaptic [20, 26–31] and, indirectly, from postsynaptic terminals .
Biosynthesis of one major endocannabinoid, anandamide, from membrane phospholipid precursors is catalysed by several enzymes. The most well-studied of these, which we measured the encoding mRNA for here, is N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD; [33, 34]), but others include glycerophosphodiesterase (GDE1) , abhydrolase domain 4 (ABHD4)  and the phosphatase PTPN22 . Formation of the other major endocannabinoid, 2-arachidonylglycerol (2-AG), is catalysed by alpha and beta diacylglycerol lipases (DAGL) . Fatty acid amide hydrolase (FAAH) catalyses postsynaptic anandamide breakdown [39, 40] while 2-AG activity is terminated by both presynaptic monoglyceride lipase (MGL) and the postsynaptic abhydrolase domain 6 enzyme (ABHD6) [41–45]. Together, these elements of the endocannabinoid signalling system regulate early nervous system development (i.e. neuroblast migration , pyramidal cell specification , interneuron migration  and axon guidance [49–51]) and synaptic plasticity [29, 52], and thus would also be expected to sculpt behavioural and cognitive development.
It is thus critical to determine the normal developmental trajectory of the endocannabinoid system, in humans and to determine which elements may be changing during critical periods such as adolescence, when the majority of cannabis use commences and which may be a period of vulnerability to the detrimental effects of cannabis exposure [53, 54]. Indeed, earlier age of cannabis use onset is associated with higher risk of psychotic symptoms and neuroanatomical abnormalities associated with psychosis [55–58]. However, while brain region-dependent increases and decreases in CB1R binding density and distribution between prenatal, infant and adult humans have been described [59–62], detailed studies of human endocannabinoid system development, particularly in the frontal cortex, are lacking. The aim of the present study was therefore to extend these earlier findings, using gene expression analysis to describe the development of CB1R and some of the major endocannabinoid metabolic enzyme mRNAs in human DLPFC across postnatal life. Given the localisation of CB1Rs to CCK-, calbindin- and calretinin-positive interneurons, we hypothesised that the trajectory of cortical CB1R development would partially correspond to those previously determined for these interneuron marker mRNAs in the same subjects .
Expression of housekeeping gene mRNAs did not change significantly over the lifespan, nor did the geometric mean of the expression for all four housekeeping genes (Additional file 1: Figure S1).
CB1R mRNA decreases across postnatal life
CB1R mRNA levels are not correlated with expression of the interneuron marker CCK
2-AG synthesising enzyme mRNA (DAGLα) and hydrolysing enzyme mRNAs (MGL and ABHD6) show dynamic, divergent patterns across postnatal life.
MGL mRNA expression (probeset 211026_s_at) was quite variable in the microarray, showing an inverted U-shaped pattern across the human lifespan with a rapid increase until 6 months of age and then a steady decline starting after age 10 (quadratic regression p < 0.05, Figure 6C). qPCR analysis confirmed the developmental downregulation of MGL mRNA expression with age (ANOVA, F = 5.1, df = 6, 47, p < 0.001, Figure 6D), and post-hoc LSD tests showed that MGL expression was significantly reduced from infant levels by school age and continued to decrease from school age until adulthood. However, qPCR data failed to confirm the early increase in MGL mRNA from neonates to infants, suggesting that the prominent pattern was one of decline.
Microarray analysis showed that ABHD6 mRNA expression (probeset 45288_at) increased during human maturation by around 50% (r = 0.627, p < 0.001, Figure 6E). By qPCR, we saw a similar pattern, but we detected a steady increase in ABHD6 mRNA expression over postnatal development and maturation by qPCR, with a plateau from school age to young adulthood followed by an increase to adult levels [ANCOVA, F = 4.1, df = 6, 49, p = 0.002, Figure 6F; ABHD6 mRNA correlated with pH (r = 0.416, p = 0.001)]. Post-hoc LSD tests showed increased ABHD6 mRNA expression in all age groups compared with neonates, and in adults compared with infants (p < 0.05).
Anandamide synthesising and hydrolysing enzyme mRNAs (NAPE-PLD and FAAH) increase across postnatal life
FAAH mRNA expression (probeset 204231_s_at) was not altered across development in the microarray (r = 0.258, p = 0.09, Figure 7C). qPCR data indicated, however, that FAAH mRNA expression increased over the lifespan (ANOVA, F = 3.0, df = 6, 48, p = 0.02, Figure 7D), with post-hoc LSD tests showing that FAAH mRNA increased by 36% from neonates to young adulthood (p < 0.05).
In situ hybridisation allowed us to determine the laminar distribution of CB1R mRNA in the DLPFC. CB1R mRNA is highest in cortical layer II in individuals aged from one month to 50 years. We observed silver grains indicative of CB1R mRNA expression densely clustered over small, interneuron-like cells in layers II, III, IV and VI and more sparsely collected over larger cells in layers III, V and VI. CB1Rs in primate DLPFC are primarily localised on CCK-positive inhibitory interneurons , but are also co-localised with the calcium binding proteins calbindin and calretinin in distinct subsets of cortical inhibitory interneurons [16, 18–20]. We did not observe a correlation between CB1R and CCK mRNA, which increases steadily from neonatal age to adulthood . However, CB1R mRNA expression was correlated with both calbindin, which follows an inverted U-shaped trajectory , and calretinin, which is highly expressed early in human development . However, since CB1R , CCK [63, 64] and calbindin mRNA  have been detected in pyramidal neurons, expression data may reflect heterogeneous origins of the mRNA signal, such as in layer V, which contains both pyramidal neurons and wide arbor interneurons. Further studies quantifying CB1R mRNA on specific cell types are necessary to resolve the developmental expression patterns of CB1R in specific interneuron types.
Developmental changes in CB1R mRNA
Peak CB1R mRNA expression was observed at neonatal age by microarray but in toddlers by qPCR, a discrepancy that may arise from the differential preference for 3’ versus 5’ transcript detection between the two techniques. Laminar analysis of in situ hybridisation indicated that CB1R mRNA expression peaks in neonates and infants in most cortical layers. These findings are confirmed by recent data from a different study showing a similar trajectory from early life to adulthood, with CB1R mRNA peaking at neonatal age then decreasing until adulthood .
The robust decrease in CB1R mRNA expression in layer II from early life to adulthood in our human cohort agrees with previous findings in primate  and suggests strong regulation of neurotransmission by CB1Rs early in life (Figure 8). It is tempting to speculate that this CB1R down-regulation results in a gradual reduction in CB1R-mediated suppression of inhibitory presynaptic neurotransmission. Indeed, the first putative drop in CB1R mRNA expression in layer II occurs around the toddler/school age group, which represents a period of increased inhibitory control in the prefrontal cortex marked by dynamic changes in inhibitory interneuron marker expression  and increased working memory ability .
Endocannabinoids in early postnatal life
The shape of the postnatal trajectory of DAGLα mRNA suggests that the capacity for synthesis of 2-AG, the major cortical endocannabinoid, increases during early postnatal life. In early life, 2-AG synthesis is also catalysed by the beta isoform of DAGL, but since expression of this isoform may decrease very early in postnatal life  it was not measured in the present study. 2-AG tone is principally regulated by the presynaptic hydrolytic enzyme MGL , which showed reduced mRNA expression over postnatal life after peaking in infancy, and also by the postsynaptic enzyme ABHD6, expression of which increased steadily from neonatal age to adulthood. In early development, MGL co-localises with CB1Rs in presynaptic terminals of developing cortical pyramidal neurons in order to regulate corticofugal axon fasciculation . Thus the role of MGL in controlling 2-AG availability may diminish once appropriate cortical-origin connections are in place. Our results suggest that the major endogenous ligand acting on the CB1R, 2-AG, may be somewhat unstable early in human life due to quite high variability in mRNA controlling synthesis and breakdown within individuals less than 5 years of age. We suggest that 2-AG may be especially influential and subject to increased regulation in early postnatal life when the CB1R and presynaptic breakdown enzyme for 2-AG are at developmentally high levels.
Endocannabinoids in adolescence
By adolescence there is a significant decrease in CB1R expression, suggesting an overall decrease in sensitivity to the effects of released endocannabinoids on neurotransmitter release. At this age, working memory performance reaches near adult levels with concomitant increases in DLPFC activity recruitment [4, 5]. However, at adolescence, DAGLα has not started to decline and MGL mRNA has just begun to decrease, while ABHD6 mRNA continues to increase, suggesting that capacity for 2-AG hydrolysis in pre- and postsynaptic compartments may be anatomically balanced at this age. Thus, maintaining the earlier steady-state levels of 2-AG, while incorporating more temporal/spatial control of 2-AG action in the face of CB1R down-regulation, may be important during adolescence. This is an intriguing possibility and agrees with the increasing endocannabinoid-mediated suppression of neurotransmitter release observed in postnatal rat hippocampus until early adolescence . Taken together, our data imply that the capacity for 2-AG signalling remains fairly steady between early postnatal life and adolescence then may decline. The gradual increase in expression at adolescence of the mRNA for anandamide hydrolytic enzyme FAAH, which is localised postsynaptically , suggests that at this point there is increased potential for control over the timing of anandamide availability for signalling at CB1R as well.
Endocannabinoids in adulthood
CB1R mRNA continues to decline until young adulthood, when individuals have attained mature levels of inhibitory control over cortical excitability. Combined with the early life increase in DAGLα and its decline in adulthood (compared with toddlerhood, school age and adolescence), our data is broadly consistent with previous work in the rat indicating that 2-AG is higher earlier in postnatal life and declines with maturation . As maturation progresses the decline in DAGLα and MGL and increase in ABHD6 mRNA reflect the potential for reduction in the amount of 2-AG available for release from the postsynaptic terminal as compared with early postnatal life (Figure 8). Combined with reduced CB1R expression at the same age, reduced 2-AG availability after adolescence might ‘release’ the endocannabinoid-mediated suppression of presynaptic neurotransmission to allow greater inhibitory input to cortical circuitry. Our data suggest an overall increase in the capacity for anandamide synthesis via the NAPE-PLD pathway during development and maturation of the human DLPFC. Neonatal NAPE-PLD expression levels increase threefold by adulthood, extending to humans previous findings of increased cortical NAPE-PLD mRNA expression from postnatal day 14 to 56 in rats  and suggesting that, as in rat brain, anandamide synthesis may be higher in maturity than in early life . There are several possible functional implications of these observations. Anandamide induces long-term depression of inhibitory synapses via transient receptor potential vanilloid 1 (TRPV1) receptors in hippocampus, striatum and developing midbrain [71–73], and since TRPV1 receptors are expressed cortically  it is possible that anandamide facilitates excitatory neurotransmission in this region in a similar manner to its effects in the hippocampus. However, if this were the case, then increased anandamide signalling would be expected to result in decreased, rather than increased inhibitory tone as maturation proceeds. On the other hand, anandamide opposes striatal 2-AG signalling by down-regulating 2-AG production , suggesting the possibility that increased NAPE-PLD expression results in greater synthetic capacity for anandamide production and consequent down-regulation of 2-AG production towards adulthood. Finally, our data must be interpreted carefully in light of the other enzymatic pathways for anandamide synthesis, including GDE1, ABHD4 and PTPN22. Future studies will benefit from investigating the postnatal developmental expression of these mRNAs.
Overall, our data show that human early postnatal life, adolescence and adulthood are characterised by distinct differences in capacities for endocannabinoid synthesis, breakdown and receptor expression, which we summarise in Figure 8. While the varying circumstances surrounding death and variable post-mortem intervals are limitations of using human brain material, these factors did not appear to obscure the major impact of age on endocannabinoid system mRNAs nor did they have a major impact on the measurements in our study. Our findings may help to identify pathophysiological mechanisms in developmental disorders characterised by compromised cortical inhibitory function such as schizophrenia [9, 11, 76, 77] and autism . For example, disruption of this dynamic postnatal maturation by exogenous cannabinoid exposure might impact processes such as cortical network oscillations, which are governed by inhibitory interneuron activity and coordinate behavioural processes such as discrimination during decision-making  and have been reported to be susceptible to suppression by CB1R agonists [79, 80]. Importantly, since adolescence is the most likely period of commencement of cannabis use, our findings emphasise the need to determine how exposure to exogenous cannabis constituents such as THC during this period affects the changes in the endocannabinoid system and its role as a gatekeeper of neurotransmission.
Summary of developmental cohort used for experiments
0.11 - 0.24
6.60 ± 0.05
22.71 ± 2.40
7.27 ± 0.18
0.25 - 0.91
6.69 ± 0.05
17.63 ± 2.72
7.57 ± 0.17
1.58 - 4.86
6.74 ± 0.07
25.67 ± 3.90
6.91 ± 0.24
7.84 - 12.97
6.73 ± 0.06
14.67 ± 2.22
7.03 ± 0.31
16.34 - 17.82
6.75 ± 0.05
18.40 ± 2.16
6.26 ± 0.53
20.14 - 25.38
6.75 ± 0.07
12.00 ± 2.21
6.91 ± 0.24
35.99 - 49.22
6.68 ± 0.09
13.83 ± 2.18
6.78 ± 0.25
0.11 - 0.24
6.56 ± 0.05
22.11 ± 1.88
7.01 ± 0.27
0.25 - 0.91
6.61 ± 0.05
17.46 ± 1.76
7.19 ± 0.19
1.58 - 4.86
6.77 ± 0.06
19.25 ± 1.89
6.85 ± 0.25
7.84 - 12.97
6.69 ± 0.07
14.43 ± 1.95
6.88 ± 0.24
15 - 17.69
6.74 ± 0.03
17.86 ± 1.47
6.60 ± 0.28
20.14 - 25.38
6.67 ± 0.08
13.67 ± 2.75
6.73 ± 0.22
35.99 - 49.22
6.60 ± 0.10
13.38 ±1 .63
6.53 ± 0.27
In situ hybridisation
0.11 - 0.24
6.60 ± 0.05
22.11 ± 1.88
7.01 ± 0.27
0.25 - 0.91
6.61 ± 0.05
17.46 ± 1.76
7.20 ± 0.19
1.58 - 4.86
6.74 ± 0.06
22.00 ± 3.22
6.83 ± 0.22
7.84 - 12.97
6.69 ± 0.07
14.43 ± 1.95
6.88 ± 0.24
15 - 17.69
6.75 ± 0.04
16.67 ± 1.02
6.64 ± 0.33
21.93 - 25.38
6.67 ± 0.09
14.43 ± 3.20
6.83 ± 0.25
35.99 – 48.69
6.45 ± 0.10
12.60 ± 1.60
6.39 ± 0.35
Total RNA isolation and RNA quality assessment
RNA isolation, quality assessment, microarray and qPCR analyses were conducted following established protocols . Total RNA was extracted for microarray and qPCR analysis from 300 mg gray matter using Trizol (Invitrogen, Carlsbad, California) according to the manufacturer’s instructions . The quality of total RNA was determined using the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, California). 100-200 ng RNA was applied to an RNA 6000 Nano LabChip, without heating prior to loading. The RNA integrity number (RIN) was used as an indicator of RNA quality, ranging from 1 – 10 (lowest - highest quality). Six samples were excluded with RIN <5.2. Cases did not differ significantly within each age group according to brain pH or RIN.
Microarray experimental design
Total RNA (n = 45) was purified through Qiagen RNA miniKit columns (Qiagen Inc, Valencia, California) according to the manufacturer’s protocol. Purified total RNA was then prepared according to the Affymetrix protocol http://www.affymetrix.com] and hybridised to HG-U133 version 2.0+ (GeneChips, Affymetrix California). Hybridised arrays were subjected to rigorous quality control including analysis of 5’:3’ ratios (included range 0.40-0.79), percent present (included range 37 - 47%), average pair-wise correlation analysis and principal component analysis, resulting in the exclusion of 3 individuals. Affymetrix Microarray Suite (MAS 5.0) and the Bioconductor package were used for image processing and data normalisation respectively. Probe sets that were 50% present in at least one of the age subgroups were retained in the analysis (33,210 probe sets retained; 61% of total number). Microarray data are available in the Gene Expression Omnibus archive under series accession number GSE13564.
Microarray and qPCR analyses
Results from the microarray experiment were confirmed using qPCR (n = 61). cDNA was synthesised in 3 reactions of 3 μg of total RNA using the Superscript First-Strand Synthesis Kit (Invitrogen) according to the manufacturer’s protocol. Pre-designed TaqMan Gene Expression Assays (Applied Biosystems, Foster City, California) were chosen for the CB1R (CNR1; Hs00275634_m1), the 2-AG synthesising enzyme diacylglycerol lipase alpha (DAGLα, Hs00391374_m1), the 2-AG inactivating enzymes monoglyceride lipase (MGL, Hs00200752_m1) and abhydrolase domain containing 6 (ABHD6, Hs0097789_m1), the anandamide synthesizing enzyme N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD, Hs00419593_m1) and the anandamide inactivating enzyme fatty acid amide hydrolase (FAAH, Hs00155015_m1). qPCR was performed with an ABI Prism 7900HT Fast real-time PCR system with a 384-well format. Measurements were performed in triplicate and relative quantities determined from a seven-point standard curve. Control wells containing no cDNA template displayed no amplification. Efficiencies of the qPCR reactions ranged from 80% to 100%, and r2 values were between 0.97 and 1.00. Outliers were excluded from qPCR analysis if their normalised expression values were greater than 2 standard deviations from the group mean. Expression levels were normalised to the geometric mean of four ‘housekeeper’ genes that did not change expression with development: hydroxymethylbilane synthase (HMBS, Hs00609297_m1), glucuronidase-b (GUSB, Hs99999908_m1), ubiquitin C (UBC, Hs00824723_m1) and cyclophilin A (PPIA, Hs99999904_m1) .
A 247 bp fragment of the human CNR1 gene cDNA, corresponding to bps 937–1183, was inserted into a pCRII vector (Invitrogen, CA, USA). Antisense riboprobes and sense strand RNAs were generated from linearised plasmid using SP6 and T7 polymerases respectively and an in vitro transcription kit as recommended by the manufacturer (Promega, WI, USA). [35S] antisense and sense riboprobes were labelled to a specific activity of ~2 x 109 cpm/μg by addition of radiolabelled UTP and were purified by ethanol precipitation.
In situ hybridisation
14-μm coronal sections of the middle frontal gyrus from the developmental cohort tissue were used (n = 56). In situ hybridisation histochemistry was performed as previously described , using two slides per case. After hybridisation and washing steps, sections were exposed to autoradiographic film (Bio-Max, Kodak) for 3 weeks. Sections were then dipped in photographic emulsion (Kodak, type II NTB) for 13 weeks and then developed and counterstained with thionine. All sections were assayed together to limit interassay variability.
Calibrated densitometric analysis (ImageJ, National Institutes of Health, http://rsb.info.nih.gov/ij/) was conducted, blind to age, on Brodmann’s area 46 of the DLPFC delineated microscopically from adjacent Nissl-stained sections. For each section, three randomly placed lines (415 μm width) were drawn perpendicular to the pial surface, traversing the entire cortical grey matter. The density of CB1R mRNA as a function of cortical depth was computed from continuous optical density measurements recorded along the length of these lines, using radioactive standards for comparison (American Radiolabeled Chemicals Inc., MO, USA). The percentage of full cortical width corresponding to the individual lamina was determined from published guidelines as follows: I (2-6%), II (14-18%), III (20-42%), IV (46-50%), V (54-68%) and VI (72-92%) [86, 87].
Normalisation and analysis of microarray data were performed using R (http://www.r-project.org) and Bioconductor software (http://www.bioconductor.org), with which differential gene expression across chronological age was analysed using linear regression. The R program was used to draw regression lines of best fit depending on the profile of gene expression changes with age. qPCR and in situ hybridisation data were analysed using PASW Statistics 18 (SPSS Inc., IL, USA). Differences in normalised mRNA expression detected by qPCR were tested with one-way analysis of variance (ANOVA) with age group as the grouping variable in all analyses. Pearson’s correlation analyses were performed on normalised qPCR mRNA expression and demographic variables, and analysis of covariance (ANCOVA) was conducted where significant correlations were observed with pH, post-mortem interval (PMI) and RIN as continuous variables. Differences in optical density of CB1R mRNA detected by in situ hybridisation were tested with two-way repeated measures ANOVA with age group as the between-subjects variable and cortical layer as the within-subjects variable. Fisher’s least significant difference (LSD) post-hoc analyses were used to identify significant differences between age groups. Simple linear regression was performed to identify predictive relationships between normalised expression of CB1R mRNA detected by qPCR and interneuron marker mRNAs of interest that were previously measured in the same cohort .
This work was supported by the Schizophrenia Research Institute, utilising infrastructure funding from New South Wales Health and the Macquarie Group Foundation, Neuroscience Research Australia and the University of New South Wales.
We acknowledge the assistance of Dr H. Ronald Zielke and Robert Vigorito of the University of Maryland Brain and Tissue Bank for Developmental Disorders. We also thank Shan Yuan Tsai, Duncan Sinclair, Heng Woon and Stu Fillman for technical assistance and Jenny Wong for design of the template for the CB1R riboprobe, and Michael Elashoff for assistance with microarray analysis.
- McBain CJ, Fisahn A: Interneurons unbound. Nat Rev Neurosci. 2001, 2 (1): 11-23.PubMedView ArticleGoogle Scholar
- Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C: Interneurons of the neocortical inhibitory system. Nat Rev Neurosci. 2004, 5 (10): 793-807. 10.1038/nrn1519.PubMedView ArticleGoogle Scholar
- Diamond A, Goldman-Rakic PS: Comparison of human infants and rhesus monkeys on Piaget's AB task: evidence for dependence on dorsolateral prefrontal cortex. Exp Brain Res. 1989, 74 (1): 24-40.PubMedView ArticleGoogle Scholar
- Crone EA, Wendelken C, Donohue S, van Leijenhorst L, Bunge SA: Neurocognitive development of the ability to manipulate information in working memory. Proc Natl Acad Sci U S A. 2006, 103 (24): 9315-9320. 10.1073/pnas.0510088103.PubMed CentralPubMedView ArticleGoogle Scholar
- Luna B, Garver KE, Urban TA, Lazar NA, Sweeney JA: Maturation of cognitive processes from late childhood to adulthood. Child Dev. 2004, 75 (5): 1357-1372. 10.1111/j.1467-8624.2004.00745.x.PubMedView ArticleGoogle Scholar
- Bourgeois J-P, Goldman-Rakic PS, Rakic P: Synaptogenesis in the prefrontal cortex of rhesus monkeys. Cereb Cortex. 1994, 4 (1): 78-96. 10.1093/cercor/4.1.78.PubMedView ArticleGoogle Scholar
- Fung SJ, Webster MJ, Weicker CS: Expression of VGluT1 and VGAT mRNAs in human dorsolateral prefrontal cortex during development and in schizophrenia. Brain Res. 2011, 1388: 22-31.PubMedView ArticleGoogle Scholar
- Webster MJ, Elashoff M, Weickert CS: Molecular evidence that cortical synaptic growth predominates during the first decade of life in humans. Int J Dev Neurosci. 2011, 29 (3): 225-236. 10.1016/j.ijdevneu.2010.09.006.PubMedView ArticleGoogle Scholar
- Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS: Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry. 2010, 167 (12): 1479-1488. 10.1176/appi.ajp.2010.09060784.PubMedView ArticleGoogle Scholar
- Fillman SG, Duncan CE, Webster MJ, Elashoff M, Weickert CS: Developmental co-regulation of the [beta] and [gamma] GABAA receptor subunits with distinct [alpha] subunits in the human dorsolateral prefrontal cortex. Int J Dev Neurosci. 2010, 28 (6): 513-519. 10.1016/j.ijdevneu.2010.05.004.PubMedView ArticleGoogle Scholar
- Duncan CE, Webster MJ, Rothmond DA, Bahn S, Elashoff M, Shannon Weickert C: Prefrontal GABAA receptor [alpha]-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res. 2010, 44 (10): 673-681. 10.1016/j.jpsychires.2009.12.007.PubMedView ArticleGoogle Scholar
- Hashimoto T, Nguyen QL, Rotaru D, Keenan T, Arion D, Beneyto M, Gonzalez-Burgos G, Lewis DA: Protracted developmental trajectories of GABAA receptor alpha1 and alpha2 subunit expression in primate prefrontal cortex. Biol Psychiatry. 2009, 65 (12): 1015-1023. 10.1016/j.biopsych.2009.01.004.PubMed CentralPubMedView ArticleGoogle Scholar
- Ben-Ari Y, Gaiarsa J-L, Tyzio R, Khazipov R: GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev. 2007, 87 (4): 1215-1284. 10.1152/physrev.00017.2006.PubMedView ArticleGoogle Scholar
- Rivera C, Voipio J, Payne JA, Ruusuvuori E, Lahtinen H, Lamsa K, Pirvola U, Saarma M, Kaila K: The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature. 1999, 397 (6716): 251-255. 10.1038/16697.PubMedView ArticleGoogle Scholar
- Hyde TM, Lipska BK, Ali T, Mathew SV, Law AJ, Metitiri OE, Straub RE, Ye T, Colantuoni C, Herman MM, et al: Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia. J Neurosci. 2011, 31 (30): 11088-11095. 10.1523/JNEUROSCI.1234-11.2011.PubMed CentralPubMedView ArticleGoogle Scholar
- Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA: Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience. 2010, 169 (4): 1651-1661. 10.1016/j.neuroscience.2010.06.011.PubMed CentralPubMedView ArticleGoogle Scholar
- Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF: Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci. 1999, 19 (11): 4544-4558.PubMedGoogle Scholar
- Morozov YM, Torii M, Rakic P: Origin, early commitment, migratory routes, and destination of cannabinoid type 1 receptor-containing interneurons. Cereb Cortex. 2009, 19 (suppl_1): i78-i89.PubMed CentralPubMedView ArticleGoogle Scholar
- Marsicano G, Lutz B: Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci. 1999, 11 (12): 4213-4225. 10.1046/j.1460-9568.1999.00847.x.PubMedView ArticleGoogle Scholar
- Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N, Freund TF: Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci. 2005, 25 (29): 6845-6856. 10.1523/JNEUROSCI.0442-05.2005.PubMedView ArticleGoogle Scholar
- Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V: Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 2006, 139 (4): 1405-1415. 10.1016/j.neuroscience.2006.02.074.PubMedView ArticleGoogle Scholar
- Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, et al: The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron. 2006, 51 (4): 455-466. 10.1016/j.neuron.2006.07.006.PubMed CentralPubMedView ArticleGoogle Scholar
- Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T, Kano M: The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci. 2006, 26 (11): 2991-3001. 10.1523/JNEUROSCI.4872-05.2006.PubMedView ArticleGoogle Scholar
- Freund TF, Katona I, Piomelli D: Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003, 83 (3): 1017-1066.PubMedView ArticleGoogle Scholar
- Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, et al: International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2. Pharmacol Rev. 2010, 62 (4): 588-631. 10.1124/pr.110.003004.PubMed CentralPubMedView ArticleGoogle Scholar
- Trettel J, Levine ES: Endocannabinoids mediate rapid retrograde signaling at interneuron right-arrow pyramidal neuron synapses of the neocortex. J Neurophysiol. 2003, 89 (4): 2334-2338.PubMedView ArticleGoogle Scholar
- Fortin DA, Levine ES: Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons. Cereb Cortex. 2007, 17 (1): 163-174.PubMedView ArticleGoogle Scholar
- Wilson RI, Nicoll RA: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001, 410 (6828): 588-592. 10.1038/35069076.PubMedView ArticleGoogle Scholar
- Ade KK, Lovinger DM: Anandamide regulates postnatal development of long-term synaptic plasticity in the rat dorsolateral striatum. J Neurosci. 2007, 27 (9): 2403-2409. 10.1523/JNEUROSCI.2916-06.2007.PubMedView ArticleGoogle Scholar
- Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgänsberger W, Rammes G: Circuitry for associative plasticity in the amygdala Involves endocannabinoid signaling. J Neurosci. 2004, 24 (44): 9953-9961. 10.1523/JNEUROSCI.2134-04.2004.PubMedView ArticleGoogle Scholar
- Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ: Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One. 2007, 2 (8): e709-10.1371/journal.pone.0000709.PubMed CentralPubMedView ArticleGoogle Scholar
- Iremonger KJ, Kuzmiski JB, Baimoukhametova DV, Bains JS: Dual Regulation of Anterograde and Retrograde Transmission by Endocannabinoids. J Neurosci. 2011, 31 (33): 12011-12020. 10.1523/JNEUROSCI.2925-11.2011.PubMedView ArticleGoogle Scholar
- Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N: Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004, 279 (7): 5298-5305.PubMedView ArticleGoogle Scholar
- Ueda N, Okamoto Y, Morishita J: N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: A novel enzyme of the [beta]-lactamase fold family releasing anandamide and other N-acylethanolamines. Life Sci. 2005, 77 (14): 1750-1758. 10.1016/j.lfs.2005.05.018.PubMedView ArticleGoogle Scholar
- Simon GM, Cravatt BF: Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem. 2008, 283 (14): 9341-9349. 10.1074/jbc.M707807200.PubMed CentralPubMedView ArticleGoogle Scholar
- Liu J, Wang L, Harvey-White J, Huang BX, Kim H-Y, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, et al: Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 2008, 54 (1): 1-7. 10.1016/j.neuropharm.2007.05.020.PubMed CentralPubMedView ArticleGoogle Scholar
- Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim H-Y, et al: A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A. 2006, 103 (36): 13345-13350. 10.1073/pnas.0601832103.PubMed CentralPubMedView ArticleGoogle Scholar
- Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams E-J, et al: Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003, 163 (3): 463-468. 10.1083/jcb.200305129.PubMed CentralPubMedView ArticleGoogle Scholar
- Cravatt BF, Lichtman AH: The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids. 2002, 121 (1–2): 135-148.PubMedView ArticleGoogle Scholar
- Egertova M, Cravatt BF, Elphick MR: Comparative analysis of fatty acid amide hydrolase and CB(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience. 2003, 119 (2): 481-496. 10.1016/S0306-4522(03)00145-3.PubMedView ArticleGoogle Scholar
- Saario SM, Savinainen JR, Laitinen JT, Jarvinen T, Niemi R: Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol. 2004, 67 (7): 1381-1387. 10.1016/j.bcp.2003.12.003.PubMedView ArticleGoogle Scholar
- Blankman JL, Simon GM, Cravatt BF: A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007, 14 (12): 1347-1356. 10.1016/j.chembiol.2007.11.006.PubMed CentralPubMedView ArticleGoogle Scholar
- Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS-J, Woodruff G, et al: The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci. 2010, 13 (8): 951-957. 10.1038/nn.2601.PubMed CentralPubMedView ArticleGoogle Scholar
- Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, et al: Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci. 2010, 13 (9): 1113-1119. 10.1038/nn.2616.PubMed CentralPubMedView ArticleGoogle Scholar
- Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002, 99 (16): 10819-10824. 10.1073/pnas.152334899.PubMed CentralPubMedView ArticleGoogle Scholar
- Oudin MJ, Gajendra S, Williams G, Hobbs C, Lalli G, Doherty P: Endocannabinoids regulate the migration of subventricular zone-derived neuroblasts in the postnatal brain. J Neurosci. 2011, 31 (11): 4000-4011. 10.1523/JNEUROSCI.5483-10.2011.PubMedView ArticleGoogle Scholar
- Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, Monory K, Marsicano G, Di Marzo V, Hurd YL, et al: Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A. 2008, 0803545105.Google Scholar
- Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, et al: Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A. 2005, 102 (52): 19115-19120. 10.1073/pnas.0509494102.PubMed CentralPubMedView ArticleGoogle Scholar
- Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, et al: Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007, 316 (5828): 1212-1216. 10.1126/science.1137406.PubMedView ArticleGoogle Scholar
- Keimpema E, Barabas K, Morozov YM, Tortoriello G, Torii M, Cameron G, Yanagawa Y, Watanabe M, Mackie K, Harkany T: Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding. J Neurosci. 2010, 30 (42): 13992-14007. 10.1523/JNEUROSCI.2126-10.2010.PubMed CentralPubMedView ArticleGoogle Scholar
- Wu CS, Zhu J, Wager-Miller J, Wang S, O'Leary D, Monory K, Lutz B, Mackie K, Lu HC: Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci. 2010, 32 (5): 693-706. 10.1111/j.1460-9568.2010.07337.x.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhu PJ, Lovinger DM: Developmental alteration of endocannabinoid retrograde signaling in the hippocampus. J Neurophysiol. 2010, 103 (2): 1123-1129. 10.1152/jn.00327.2009.PubMed CentralPubMedView ArticleGoogle Scholar
- Malone DT, Hill MN, Rubino T: Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol. 2010, 160 (3): 511-522. 10.1111/j.1476-5381.2010.00721.x.PubMed CentralPubMedView ArticleGoogle Scholar
- Verrico CD, Liu S, Bitler EJ, Gu H, Sampson AR, Bradberry CW, Lewis DA: Delay- and dose-dependent effects of [delta]9-tetrahydrocannabinol administration on spatial and object working memory tasks in adolescent rhesus monkeys. Neuropsychopharmacology. 2012, 37 (6): 1357-1366. 10.1038/npp.2011.321.PubMed CentralPubMedView ArticleGoogle Scholar
- Dragt S, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, de Haan L, van Amelsvoort TA, Linszen DH: Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry. 2010, 55 (3): 165.PubMedGoogle Scholar
- Cohen M, Rasser PE, Peck G, Carr VJ, Ward PB, Thompson PM, Johnston P, Baker A, Schall U: Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int J Neuropsychopharmacol. 2011, FirstView: 1-11.Google Scholar
- Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE: Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002, 325 (7374): 1212-1213. 10.1136/bmj.325.7374.1212.PubMed CentralPubMedView ArticleGoogle Scholar
- Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR: Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology. 1999, 142 (3): 295-301. 10.1007/s002130050892.PubMedView ArticleGoogle Scholar
- Mato S, Del Olmo E, Pazos A: Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci. 2003, 17 (9): 1747-1754. 10.1046/j.1460-9568.2003.02599.x.PubMedView ArticleGoogle Scholar
- Glass M, Dragunow M, Faull RL: Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997, 77 (2): 299-318. 10.1016/S0306-4522(96)00428-9.PubMedView ArticleGoogle Scholar
- Biegon A, Kerman IA: Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage. 2001, 14 (6): 1463-1468. 10.1006/nimg.2001.0939.PubMedView ArticleGoogle Scholar
- Wang X, Dow-Edwards D, Keller E, Hurd YL: Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience. 2003, 118 (3): 681-694. 10.1016/S0306-4522(03)00020-4.PubMedView ArticleGoogle Scholar
- Burgunder JM, Young WS: Cortical neurons expressing the cholecystokinin gene in the rat: distribution in the adult brain, ontogeny, and some of their projections. J Comp Neurol. 1990, 300 (1): 26-46. 10.1002/cne.903000104.PubMedView ArticleGoogle Scholar
- Hökfelt T, Morino P, Vergeb V, Castel MN, Broberger C, Zhang X, Herrera-Marschitz M, Meana JJ, Ungerstedt U, Xu XJ, et al: CCK in Cerebral Cortex and at the Spinal Level. Ann NY Acad Sci. 1994, 713 (1): 157-163. 10.1111/j.1749-6632.1994.tb44062.x.PubMedView ArticleGoogle Scholar
- Hayes TL, Lewis DA: Nonphosphorylated neurofilament protein and calbindin immunoreactivity in layer III pyramidal neurons of human neocortex. Cereb Cortex. 1992, 2 (1): 56-67. 10.1093/cercor/2.1.56.PubMedView ArticleGoogle Scholar
- Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, Sousa AM, Pletikos M, Meyer KA, Sedmak G, et al: Spatio-temporal transcriptome of the human brain. Nature. 2011, 478 (7370): 483-489. 10.1038/nature10523.PubMed CentralPubMedView ArticleGoogle Scholar
- Eggan SM, Mizoguchi Y, Stoyak SR, Lewis DA: Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cereb Cortex. 2010, 20 (5): 1164-1174. 10.1093/cercor/bhp179.PubMed CentralPubMedView ArticleGoogle Scholar
- Diamond A: Development of the ability to use recall to guide action, as indicated by infants' performance on AB. Child Dev. 1985, 56 (4): 868-883. 10.2307/1130099.PubMedView ArticleGoogle Scholar
- Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ: Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse. 1999, 33 (3): 181-191. 10.1002/(SICI)1098-2396(19990901)33:3<181::AID-SYN3>3.0.CO;2-R.PubMedView ArticleGoogle Scholar
- Morishita J, Okamoto Y, Tsuboi K, Ueno M, Sakamoto H, Maekawa N, Ueda N: Regional distribution and age-dependent expression of N-acylphosphatidylethanolamine-hydrolyzing phospholipase D in rat brain. J Neurochem. 2005, 94 (3): 753-762. 10.1111/j.1471-4159.2005.03234.x.PubMedView ArticleGoogle Scholar
- Chavez AE, Chiu CQ, Castillo PE: TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci. 2010, 13 (12): 1511-1518. 10.1038/nn.2684.PubMed CentralPubMedView ArticleGoogle Scholar
- Grueter BA, Brasnjo G, Malenka RC: Postsynaptic TRPV1 triggers cell type-specific long-term depression in the nucleus accumbens. Nat Neurosci. 2010, 13 (12): 1519-1525. 10.1038/nn.2685.PubMed CentralPubMedView ArticleGoogle Scholar
- Maione S, Cristino L, Migliozzi AL, Georgiou AL, Starowicz K, Salt TE, Di Marzo V: TRPV1 channels control synaptic plasticity in the developing superior colliculus. J Physiol. 2009, 587 (Pt 11): 2521-2535.PubMed CentralPubMedView ArticleGoogle Scholar
- Liapi A, Wood JN: Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur J Neurosci. 2005, 22 (4): 825-834. 10.1111/j.1460-9568.2005.04270.x.PubMedView ArticleGoogle Scholar
- Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, Gasperi V, Prosperetti C, Bernardi G, Finazzi-Agro A, et al: Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci. 2008, 11 (2): 152-159. 10.1038/nn2042.PubMedView ArticleGoogle Scholar
- Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA: Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry. 2000, 57 (3): 237-245. 10.1001/archpsyc.57.3.237.PubMedView ArticleGoogle Scholar
- Lewis DA, Gonzalez-Burgos G: Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology. 2007, 33 (1): 141-165.PubMedView ArticleGoogle Scholar
- Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O/'Shea DJ, Sohal VS, Goshen I, Finkelstein J, Paz JT, et al: Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature. 2011, advance online publicationGoogle Scholar
- Hajós M, Hoffmann WE, Kocsis B: Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry. 2008, 63 (11): 1075-1083. 10.1016/j.biopsych.2007.12.005.PubMedView ArticleGoogle Scholar
- Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, Freund TF: Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci. 2000, 12 (9): 3239-3249. 10.1046/j.1460-9568.2000.00217.x.PubMedView ArticleGoogle Scholar
- Wong J, Webster MJ, Cassano H, Weickert CS: Changes in alternative brain-derived neurotrophic factor transcript expression in the developing human prefrontal cortex. Eur J Neurosci. 2009, 29 (7): 1311-1322. 10.1111/j.1460-9568.2009.06669.x.PubMedView ArticleGoogle Scholar
- Weickert CS, Elashoff M, Richards AB, Sinclair D, Bahn S, Paabo S, Khaitovich P, Webster MJ: Transcriptome analysis of male–female differences in prefrontal cortical development. Mol Psychiatry. 2009, 14 (6): 558-561. 10.1038/mp.2009.5.PubMedView ArticleGoogle Scholar
- Kozlovsky N: Shannon Weickert C, Tomaskovic-Crook E, Kleinman JE, Belmaker RH, Agam G: Reduced GSK-3ß mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J Neural Transm. 2004, 111 (12): 1583-1592. 10.1007/s00702-004-0166-3.PubMedView ArticleGoogle Scholar
- Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull RLM, McKenna PJ, Jones PB, Arai H, Starkey M, et al: Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci U S A. 2002, 99 (7): 4680-4685. 10.1073/pnas.032069099.PubMed CentralPubMedView ArticleGoogle Scholar
- Whitfield HJ, Brady LS, Smith MA, Mamalaki E, Fox RJ, Herkenham M: Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: a detailed protocol. Cell Mol Neurobiol. 1990, 10 (1): 145-157. 10.1007/BF00733641.PubMedView ArticleGoogle Scholar
- Romanczyk TB, Weickert CS, Webster MJ, Herman MM, Akil M, Kleinman JE: Alterations in trkB mRNA in the human prefrontal cortex throughout the lifespan. Eur J Neurosci. 2002, 15 (2): 269-280. 10.1046/j.0953-816x.2001.01858.x.PubMedView ArticleGoogle Scholar
- Rajkowska G, Goldman-Rakic PS: Cytoarchitectonic definition of prefrontal areas in the normal human cortex: II. Variability in locations of areas 9 and 46 and relationship to the Talairach Coordinate System. Cereb Cortex. 1995, 5 (4): 323-337. 10.1093/cercor/5.4.323.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.